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Introduction
The lifetime risk of developing HTLV-1 associated mye-
lopathy (HAM) is 0.25-3%. The main pathological fea-
ture is an immune-mediated response leading to chronic
inflammation of the spinal cord. The optimal long term
treatment has yet to be determined although clinical
improvement with ciclosporin has been shown in a pilot
study. Methotrexate, commonly used for autoimmune
diseases, was introduced for the treatment of HAM at
the National Centre for Human Retrovirology, London,
UK as an alternative to ciclosporin.
Methods
A retrospective study of patients with chronic HAM
treated with methotrexate. Primary outcomes are clinical
both objective and subjective using routine clinic data.
Secondary outcomes virological/immunological. Metho-
trexate was prescribed weekly at an initial dose of 7.5mg
and a maximum dose of 15mg with weekly folic acid
supplementation.
Results
Duration of methotrexate 4 – 59 weeks. Generally well
tolerated. Four haematological toxicities all grade 1/2
and three liver toxicities two grade 3/4 - one treatment
discontinuation due to asymptomatic liver toxicity.
Objective measure – Compared with baseline -57.39s
(18.8-120) mean 10m timed walk improved within
4 weeks 34.54s (16.8-87), p=0.0151. The overall trend
shows persistent improvement.
Subjective- Pain as measured on a Visual Analogue
Scale improved over the duration of treatment with the
greatest improvement occurring within the first 4 weeks
of treatment. Virology and Immunological. T-cell
activation markers, Th1/2 cytokine data and HTLV viral
load data will be presented.
Conclusions
These preliminary data suggest that methotrexate may be
beneficial for some patients with HAM and is a suitable
candidate for a randomised controlled study.
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